Maynard Um
-
-
-
-
-
-
-
Nektar presents early biomarker data for eczema drug at EADV 2026
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) PT Raised to $95 at Wedbush
-
-
-
-
-
-
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
-
-
-
-
-
-
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR)
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) PT Raised to $115 at Oppenheimer
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) on Watch Following M&A Chatter
-
-
-
-
-
-
-
Nektar Therapeutics (NKTR) Misses Q2 EPS by 258c
-
465,001 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


